![]() Gary Ackerman, an associate professor and associate dean at the College of Emergency Preparedness, Homeland Security and Cybersecurity (CEHC) writes that one of the ways terrorists can get leverage is through an enabling technology like AI, by hacking into an existing AI that, for example, controlled nuclear weapons systems and set off nuclear war. If the defence and highly regulated industries are unlikely to deploy Generative AI in the short to medium term for mission critical use cases due to its performance meeting accuracy targets, is the AI existential threat real or perceived? Hedge fund quants using algorithmic and high frequency trading strategies will also set a high bar for Generative AI. Defense Department recently told a conference, “I need five nines – 99.999 percent accuracy – of correctness.” Soldiers using AI cannot afford mistakes literally blowing up in their faces.įinancial services institutions are likely to be sceptical about the performance of Generative AI and its use cases in highly regulated businesses that require accuracy. Craig Martell, chief digital and AI officer at the US. ![]() Some generative AI models, such as Bing Chat or GPT-4 are providing footnotes with sources that tell users where the response is coming from and to check its accuracy.įor some potential customers, that accuracy will never be good enough. Tech companies are working to improve their models. People who have used ChatGPT will have noticed that it can make mistakes and makes up facts simply because it does not have the right data. Those revenues genuinely could grow by 1000x, but that’s mighty speculative.” The valuations anticipate trillion-dollar markets, but the actual current revenues from Generative AI are rumoured to be in the hundreds of millions. Gary Marcus, Emeritus Professor of Psychology and Neural Science at NYU and a founder of the Center for the Advancement of Trustworthy AI, writes “The revenue isn’t there yet, and might never come. Is Generative AI All Hype?įor every winner there is a loser, and there will be plenty of losers in the generative AI investment craze. Kevin was also involved in the establishment of the Connecticut Stem Cell Fund and managed CII’s PreSeed program, which makes investment in very early-stage companies with small convertible-debt instruments.Analysts are urging investors to focus on companies that generate revenue from AI or use it to gain a strategic edge and improve products, over companies that are pre-revenue or cash negative and talking up future values. He managed CII’s $46 million BioFacilities Fund, which invested in wet laboratory space for bioscience companies, and managed CII’s two incubator laboratories in Science Park in New Haven. Kevin is a founding member and on the board of the UConn Innovation Fund, a partnership with Webster Bank, UConn and CII that makes investments in UConn-related technologies. He was on the board of Standing Stone when it was sold to Alere. ![]() Since joining CII in 2006, Kevin has led investments in, Torigen Pharmaceuticals, Affinimark Technologies, Cara Therapeutics (IPO), CaroGen Corporation, Discover Video, HistoRx (sold to Genoptix), Intelligent Clearing Network, Oil Purification Systems, Oxford Performance Materials, Perosphere, Precipio Diagnostics (IPO), Rapid Oxygen and Solais Lighting (sold to PowerSecure),BioWave Corporation, Point Pickup, WellLinks, Inc,Mininvasive Orthopedics Solutions, OmniCyte and others. He is a Senior Managing Director, Investments, at Connecticut Innovations (CII). Kevin is a board member of TREBEL, a position he has held since 2017.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |